Logo image of GDS.PA

RAMSAY GENERALE DE SANTE SA (GDS.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:GDS - FR0000044471 - Common Stock

9.28 EUR
+0.08 (+0.87%)
Last: 12/31/2025, 7:00:00 PM
Fundamental Rating

2

GDS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 28 industry peers in the Health Care Providers & Services industry. GDS may be in some trouble as it scores bad on both profitability and health. GDS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

GDS had negative earnings in the past year.
GDS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GDS reported negative net income in multiple years.
In the past 5 years GDS always reported a positive cash flow from operatings.
GDS.PA Yearly Net Income VS EBIT VS OCF VS FCFGDS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

GDS has a Return On Assets of -0.79%. This is amonst the worse of the industry: GDS underperforms 82.14% of its industry peers.
The Return On Equity of GDS (-4.72%) is worse than 82.14% of its industry peers.
The Return On Invested Capital of GDS (2.64%) is worse than 78.57% of its industry peers.
GDS had an Average Return On Invested Capital over the past 3 years of 1.89%. This is significantly below the industry average of 6.91%.
The last Return On Invested Capital (2.64%) for GDS is above the 3 year average (1.89%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.79%
ROE -4.72%
ROIC 2.64%
ROA(3y)-0.29%
ROA(5y)0.37%
ROE(3y)-1.76%
ROE(5y)2.11%
ROIC(3y)1.89%
ROIC(5y)1.48%
GDS.PA Yearly ROA, ROE, ROICGDS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10

1.3 Margins

With a Operating Margin value of 3.57%, GDS is not doing good in the industry: 64.29% of the companies in the same industry are doing better.
In the last couple of years the Operating Margin of GDS has grown nicely.
With an excellent Gross Margin value of 77.91%, GDS belongs to the best of the industry, outperforming 82.14% of the companies in the same industry.
GDS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.57%
PM (TTM) N/A
GM 77.91%
OM growth 3Y29.81%
OM growth 5Y22.78%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5Y-0.65%
GDS.PA Yearly Profit, Operating, Gross MarginsGDS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

2

2. Health

2.1 Basic Checks

GDS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
GDS has about the same amout of shares outstanding than it did 1 year ago.
GDS has about the same amout of shares outstanding than it did 5 years ago.
GDS has a worse debt/assets ratio than last year.
GDS.PA Yearly Shares OutstandingGDS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
GDS.PA Yearly Total Debt VS Total AssetsGDS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

GDS has an Altman-Z score of 1.00. This is a bad value and indicates that GDS is not financially healthy and even has some risk of bankruptcy.
GDS has a worse Altman-Z score (1.00) than 71.43% of its industry peers.
The Debt to FCF ratio of GDS is 7.41, which is on the high side as it means it would take GDS, 7.41 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 7.41, GDS is in the better half of the industry, outperforming 67.86% of the companies in the same industry.
A Debt/Equity ratio of 3.27 is on the high side and indicates that GDS has dependencies on debt financing.
With a Debt to Equity ratio value of 3.27, GDS is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.27
Debt/FCF 7.41
Altman-Z 1
ROIC/WACC0.59
WACC4.5%
GDS.PA Yearly LT Debt VS Equity VS FCFGDS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

A Current Ratio of 0.81 indicates that GDS may have some problems paying its short term obligations.
The Current ratio of GDS (0.81) is worse than 67.86% of its industry peers.
GDS has a Quick Ratio of 0.81. This is a bad value and indicates that GDS is not financially healthy enough and could expect problems in meeting its short term obligations.
GDS has a Quick ratio (0.73) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.73
GDS.PA Yearly Current Assets VS Current LiabilitesGDS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

1

3. Growth

3.1 Past

The earnings per share for GDS have decreased by -0.37% in the last year.
Looking at the last year, GDS shows a small growth in Revenue. The Revenue has grown by 4.70% in the last year.
Measured over the past years, GDS shows a small growth in Revenue. The Revenue has been growing by 6.95% on average per year.
EPS 1Y (TTM)-0.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.93%
Revenue 1Y (TTM)4.7%
Revenue growth 3Y6.82%
Revenue growth 5Y6.95%
Sales Q2Q%3.73%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GDS.PA Yearly Revenue VS EstimatesGDS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2

4. Valuation

4.1 Price/Earnings Ratio

GDS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GDS.PA Price Earnings VS Forward Price EarningsGDS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GDS is valued a bit cheaper than the industry average as 78.57% of the companies are valued more expensively.
GDS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GDS is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1.86
EV/EBITDA 7.57
GDS.PA Per share dataGDS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for GDS!.
Industry RankSector Rank
Dividend Yield 0%

RAMSAY GENERALE DE SANTE SA

EPA:GDS (12/31/2025, 7:00:00 PM)

9.28

+0.08 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-13 2025-11-13
Earnings (Next)02-24 2026-02-24
Inst Owners39.92%
Inst Owner ChangeN/A
Ins Owners6.67%
Ins Owner ChangeN/A
Market Cap1.02B
Revenue(TTM)5.24B
Net Income(TTM)-54.10M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.2
P/FCF 1.86
P/OCF 1.48
P/B 0.89
P/tB N/A
EV/EBITDA 7.57
EPS(TTM)-0.49
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.99
FCFY53.78%
OCF(TTM)6.28
OCFY67.72%
SpS47.49
BVpS10.37
TBVpS-10.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.79%
ROE -4.72%
ROCE 3.59%
ROIC 2.64%
ROICexc 2.85%
ROICexgc 5.42%
OM 3.57%
PM (TTM) N/A
GM 77.91%
FCFM 10.51%
ROA(3y)-0.29%
ROA(5y)0.37%
ROE(3y)-1.76%
ROE(5y)2.11%
ROIC(3y)1.89%
ROIC(5y)1.48%
ROICexc(3y)2.04%
ROICexc(5y)1.59%
ROICexgc(3y)3.83%
ROICexgc(5y)2.97%
ROCE(3y)2.58%
ROCE(5y)2.01%
ROICexgc growth 3Y44.11%
ROICexgc growth 5Y31.78%
ROICexc growth 3Y41.72%
ROICexc growth 5Y29.83%
OM growth 3Y29.81%
OM growth 5Y22.78%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.59%
GM growth 5Y-0.65%
F-Score3
Asset Turnover0.77
Health
Industry RankSector Rank
Debt/Equity 3.27
Debt/FCF 7.41
Debt/EBITDA 6.03
Cap/Depr 32.9%
Cap/Sales 2.72%
Interest Coverage 0.99
Cash Conversion 111.64%
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.73
Altman-Z 1
F-Score3
WACC4.5%
ROIC/WACC0.59
Cap/Depr(3y)38.37%
Cap/Depr(5y)42.77%
Cap/Sales(3y)3.25%
Cap/Sales(5y)3.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.93%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.7%
Revenue growth 3Y6.82%
Revenue growth 5Y6.95%
Sales Q2Q%3.73%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y51.13%
EBIT growth 3Y38.66%
EBIT growth 5Y31.31%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y31.7%
FCF growth 3Y99.96%
FCF growth 5Y-0.36%
OCF growth 1Y18.22%
OCF growth 3Y38.26%
OCF growth 5Y-1%

RAMSAY GENERALE DE SANTE SA / GDS.PA FAQ

Can you provide the ChartMill fundamental rating for RAMSAY GENERALE DE SANTE SA?

ChartMill assigns a fundamental rating of 2 / 10 to GDS.PA.


What is the valuation status of RAMSAY GENERALE DE SANTE SA (GDS.PA) stock?

ChartMill assigns a valuation rating of 2 / 10 to RAMSAY GENERALE DE SANTE SA (GDS.PA). This can be considered as Overvalued.


How profitable is RAMSAY GENERALE DE SANTE SA (GDS.PA) stock?

RAMSAY GENERALE DE SANTE SA (GDS.PA) has a profitability rating of 3 / 10.


Can you provide the dividend sustainability for GDS stock?

The dividend rating of RAMSAY GENERALE DE SANTE SA (GDS.PA) is 0 / 10 and the dividend payout ratio is 0%.